Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapid symptom relief in rhinitis.

J Bousquet1

  • 1CHU Montpellier, Hôpital Arnaud de Villeneuve, France.

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|April 21, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids.

Steroids·2001
Same author

Apoptosis and airway inflammation in asthma.

Apoptosis : an international journal on programmed cell death·2001
Same author

Visualisation of the portal flows by porto-scanner.

Surgical and radiologic anatomy : SRA·2001
Same author

Phase II trial of chronomodulated infusion of 5-fluorouracil and folinic acid in metastatic colorectal cancer.

Anticancer research·2001
Same author

[Vaccination with allergens in children].

Allergie et immunologie·2001
Same author

Basophils and exercise-induced hypoxemia in extreme athletes.

Journal of applied physiology (Bethesda, Md. : 1985)·2001

Mizolastine provides rapid relief for allergic rhinitis symptoms, demonstrating faster and more effective symptom reduction than cetirizine within the first 12 hours of treatment. This antihistamine is effective for both seasonal and perennial allergic rhinitis.

Area of Science:

  • Allergy and Immunology
  • Pharmacology
  • Otorhinolaryngology

Background:

  • Severe allergic rhinitis necessitates rapid symptom relief.
  • Current first-line treatments like H1 blockers and topical corticosteroids have limitations in onset speed.
  • Rapid onset of action is a key criterion for selecting rhinitis medications.

Purpose of the Study:

  • To evaluate the onset and efficacy of mizolastine compared to cetirizine and placebo in allergic rhinitis.
  • To assess mizolastine's effectiveness in both seasonal allergic rhino-conjunctivitis (SAR) and perennial allergic rhino-conjunctivitis (PAR).

Main Methods:

  • Two multicentric, randomized, placebo-controlled studies were conducted.
  • Study 1 compared mizolastine (10 mg once daily) with cetirizine (10 mg once daily) and placebo in 375 SAR patients.

Related Experiment Videos

  • Study 2 compared mizolastine with placebo in 257 PAR patients over 4 weeks, using diary cards for symptom recording.

    • Main Results:

    • Both mizolastine and cetirizine significantly reduced SAR symptoms compared to placebo, with rapid onset within 2 hours.
    • Mizolastine showed a more rapid and profound effect than cetirizine within the first 12 hours for SAR.
    • Mizolastine significantly reduced nasal and ocular symptoms in PAR patients compared to placebo from day 1.

    Conclusions:

    • Mizolastine is an effective treatment for both SAR and PAR, offering rapid symptom relief.
    • Mizolastine demonstrates a faster onset of action and superior initial efficacy compared to cetirizine.
    • The study supports rapid onset of action as a crucial factor in allergic rhinitis treatment selection.